lncRNA CCAT1 is a biomarker for the proliferation and drug resistance of esophageal cancer via the miR‐143/PLK1/BUBR1 axis

Emerging roles of long non-coding RNA in cancer

(2018) Anna Sanchez Calle et al.   CANCER SCIENCE

Emerging role of long non-coding RNAs in cisplatin resistance

(2018) Yang Hu et al.   OncoTargets and Therapy

Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis

(2016) Yuan Wang et al.   CANCER LETTERS

CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer

(2016) Mark L. McCleland et al.   JOURNAL OF CLINICAL INVESTIGATION

MiR-143-3p functions as a tumor suppressor by regulating cell proliferation, invasion and epithelial–mesenchymal transition by targeting QKI-5 in esophageal squamous cell carcinoma

(2016) Zhenyue He et al.   Molecular Cancer

Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics

(2016) Rosie Elizabeth Ann Gutteridge et al.   MOLECULAR CANCER THERAPEUTICS

H3K27 acetylation activated-long non-coding RNA CCAT1 affects cell proliferation and migration by regulating SPRY4 and HOXB13 expression in esophageal squamous cell carcinoma

(2016) Erbao Zhang et al.   NUCLEIC ACIDS RESEARCH

Long noncoding RNA CCAT1 promotes hepatocellular carcinoma progression by functioning as let-7 sponge

(2015) Liang Deng et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The emerging role of lncRNAs in cancer

(2015) Maite Huarte   NATURE MEDICINE

Pan-cancer transcriptome analysis reveals long noncoding RNAs with conserved function

(2015) Christopher R Cabanski et al.   RNA Biology

Deregulation of miR-93 and miR-143 in human esophageal cancer

(2015) Mohammad Hossein Ansari et al.   TUMOR BIOLOGY

Long non-coding RNA CCAT1 promotes gallbladder cancer development via negative modulation of miRNA-218-5p

(2015) M-Z Ma et al.   Cell Death & Disease

Colon Cancer Associated Transcript-1 (CCAT1) Expression in Adenocarcinoma of the Stomach

(2015) Ido Mizrahi et al.   Journal of Cancer

Long noncoding RNAs: a potential novel class of cancer biomarkers

(2015) Aliaksandr A. Yarmishyn et al.   Frontiers in Genetics

Esophageal Carcinoma

(2014) Anil K. Rustgi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-range interaction and correlation between MYC enhancer and oncogenic long noncoding RNA CARLo-5

(2014) T. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion

(2014) Xiaolu He et al.   TUMOR BIOLOGY

Epidemiology of esophageal cancer

(2014) Yuwei Zhang   WORLD JOURNAL OF GASTROENTEROLOGY

Differential expression of colon cancer associated transcript1 (CCAT1) along the colonic adenoma-carcinoma sequence

(2013) Bilal Alaiyan et al.   BMC CANCER

Treatment options for esophageal squamous cell carcinoma

(2013) Masanobu Nakajima et al.   EXPERT OPINION ON PHARMACOTHERAPY

RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts

(2013) Sarah Geisler et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Abnormal expression of the mitotic checkpoint protein BubR1 contributes to the anti-microtubule drug resistance of esophageal squamous cell carcinoma cells

(2012) MIN HU et al.   ONCOLOGY REPORTS

Small RNA Sequencing and Functional Characterization Reveals MicroRNA-143 Tumor Suppressor Activity in Liposarcoma

(2011) S. Ugras et al.   CANCER RESEARCH

Reciprocal Activation Between PLK1 and Stat3 Contributes to Survival and Proliferation of Esophageal Cancer Cells

(2011) Yu Zhang et al.   GASTROENTEROLOGY

Colon cancer associated transcript-1: A novel RNA expressed in malignant and pre-malignant human tissues

(2011) Aviram Nissan et al.   INTERNATIONAL JOURNAL OF CANCER

BI 6727, A Polo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad Antitumor Activity

(2009) D. Rudolph et al.   CLINICAL CANCER RESEARCH

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

(2009) Puneet Chopra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS